The independent source for health policy research, polling, and news.
821 - 840 of 990 Results
As lawmakers look for ways to stabilize the health law marketplaces, a number of ideas ā such as expanding who can ābuy inā to Medicare and Medicaid or pushing young adults off their parentsā plans into the marketplaces ā might come into play.
In this episode of āWhat the Health?ā Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Margot Sanger-Katz of The New York Times discuss the continuing efforts in Congress to ārepeal and replaceā the Affordable Care Act, upcoming open enrollment for individual insurance and Congressā long health care to-do list for September.
Politicians who tried to take health care benefits from their voters may face political consequences as constituents come to understand whatās at stake ā in a way they didnāt a few months ago.
In this episode of āWhat the Health?ā Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Actās marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
Majorities of Democrats and Republicans ā and people who say they are supporters of President Donald Trump ā say they want the country to make the law successful.
In this episode of āWhat the Health?ā Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Sarah Kliff of Vox.com, and Margot Sanger-Katz of The New York Times discuss the state of the individual health insurance markets in the wake of the failure (for now) of Congressās efforts to repeal and replace the Affordable Care Act.
Sen. Patty Murray questions Dr. Brett Giroirās willingness to stand up for womenās health programs such as family planning services and teenage pregnancy prevention.
The small federal program once based funding on an areaās cumulative number of cases. It will now be more responsive to places where new outbreaks are occurring.
By taking aim at the subsidies received by some congressional staff members who, under the Affordable Care Act, are mandated to get their health coverage from the Obamacare exchanges, the president reignited an old fight.
The Trump administration is poised to grant states waivers that some critics say could change the shape of the program.
In this episode of āWhat the Health?ā Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Sarah Kliff of Vox.com, and Mary Agnes Carey of Kaiser Health News deconstruct the drama leading to the middle-of-the-night collapse of Senate Republicansā last-ditch effort to overhaul the Affordable Care Act.
As postmortems mount regarding the collapse of the Senate Republican health plan, itās clear how complex political and policy issues worked against the replacement effort.
The Affordable Care Act has repeatedly faced opposition in Congress and the courts, but it has continued to survive.
The Affordable Care Act has repeatedly faced opposition in Congress and the courts, but it has continued to survive.
After a late-night session and the "skinny" defeat, Senate Majority Leader Mitch McConnell pulls legislation to repeal the Affordable Care Act from the floor.
Republican senators are warming to the idea of a scaled-back plan that would delete the Affordable Care Actās individual and employer mandates but leave the rest of law generally intact. But this approach has caused difficulties in the past.
The Senateās vote to proceed with debate on an Obamacare repeal bill had drama and plenty of color, but you couldnāt get the complete picture on TV.
The deliberations will be strictly governed by a time limit on debate and strict rules about what is germane.
In a head-to-head comparison, several of the cheaper devices performed nearly as well as the expensive hearing aids. The study lends credence to lawmakersā efforts to get the FDA to set standards for over-the-counter versions.
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
Ā© 2026 KFF